These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17233186)

  • 1. Drug-drug interactions and statin therapy.
    Trifiro G
    South Med J; 2006 Dec; 99(12):1325-6. PubMed ID: 17233186
    [No Abstract]   [Full Text] [Related]  

  • 2. Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?
    Langford NJ; Kendall MJ
    J Clin Pharm Ther; 2001 Dec; 26(6):391-5. PubMed ID: 11722675
    [No Abstract]   [Full Text] [Related]  

  • 3. [Drug interactions with antilipemics].
    Becquemont L
    Therapie; 2003; 58(1):85-90. PubMed ID: 12822205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin safety and drug interactions: clinical implications.
    Bottorff MB
    Am J Cardiol; 2006 Apr; 97(8A):27C-31C. PubMed ID: 16581325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
    Neuvonen PJ
    Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug-induced myopathies].
    Ando H; Fujimura A
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():390-3. PubMed ID: 18074569
    [No Abstract]   [Full Text] [Related]  

  • 7. [Rhabdomyolysis induced by statins].
    Hamano T; Muto T; Kuriyama M
    Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1646-51. PubMed ID: 17802715
    [No Abstract]   [Full Text] [Related]  

  • 8. [HMG-CoA reductase inhibitors (statin)].
    Yamamura T; Ishigami M
    Nihon Rinsho; 2007 Jul; 65 Suppl 7():458-64. PubMed ID: 17824071
    [No Abstract]   [Full Text] [Related]  

  • 9. Needed: pragmatic clinical trials for statin-intolerant patients.
    Maningat P; Breslow JL
    N Engl J Med; 2011 Dec; 365(24):2250-1. PubMed ID: 22085320
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug interactions and the statins.
    Herman RJ
    CMAJ; 1999 Nov; 161(10):1281-6. PubMed ID: 10584091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of lipid-lowering agents (statins) during pregnancy.
    Hosokawa A; Bar-Oz B; Ito S
    Can Fam Physician; 2003 Jun; 49():747-9. PubMed ID: 12836860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How well tolerated are lipid-lowering drugs?
    Tomlinson B; Chan P; Lan W
    Drugs Aging; 2001; 18(9):665-83. PubMed ID: 11599634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Statins and muscular adverse effects].
    Bekken R
    Tidsskr Nor Laegeforen; 2001 Feb; 121(5):630. PubMed ID: 11301630
    [No Abstract]   [Full Text] [Related]  

  • 14. Rhabdomyolysis and lipid-lowering drugs.
    Tenenbaum A; Fisman EZ; Motro M
    JAMA; 2005 Mar; 293(12):1448; author reply 1448-9. PubMed ID: 15784863
    [No Abstract]   [Full Text] [Related]  

  • 15. Perioperative statin therapy may be implicated in a wide array of drug-drug interactions.
    Marcucci C; Hutchens MP; Sandson NB
    Anesthesiology; 2009 Jul; 111(1):205; author reply 205-6. PubMed ID: 19546699
    [No Abstract]   [Full Text] [Related]  

  • 16. Limitations of a meta-analysis investigating the association between cancer and statin use.
    Iwata H; Aoyama T; Kusumi E; Hamaki T; Kami M
    Am J Med; 2002 Feb; 112(2):157-8. PubMed ID: 11835959
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hypolipidemic agents drug interactions: approach to establish and assess its clinical significance. Structured review].
    Franco D; Henao Y; Monsalve M; Gutiérrez F; Hincapie J; Amariles P
    Farm Hosp; 2013; 37(6):539-57. PubMed ID: 24256019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of antilipidemic agents: facts and fictions.
    Xydakis AM; Jones PH
    Curr Atheroscler Rep; 2003 Sep; 5(5):403-10. PubMed ID: 12911851
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipid-lowering agents and risk of melanoma.
    Kirsner RS; Ramirez CC; Federman DG; Ma F
    Int J Cancer; 2005 Nov; 117(2):333; author reply 334. PubMed ID: 15900582
    [No Abstract]   [Full Text] [Related]  

  • 20. [HMG-CoA reductase inhibitors].
    Yamamoto A
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():578-86. PubMed ID: 11347135
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.